<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772729</url>
  </required_header>
  <id_info>
    <org_study_id>TIR: Fiasp vs. Asp</org_study_id>
    <nct_id>NCT04772729</nct_id>
  </id_info>
  <brief_title>Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?</brief_title>
  <official_title>Does the Use of Faster Insulin Aspart vs. Aspart Lead to the Prolonged Glycemic Time in Range in Children Suffering From Type 1 Diabetes Who Use Continuous Glucose Monitoring?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess whether the implementation of faster insulin aspart in&#xD;
      children with Type 1 diabetes treated with intensive insulin therapy with the use of an&#xD;
      insulin pump and using Real Time Continuous Glucose Monitoring (RT-CGM) systems leads to&#xD;
      prolonged time in range (TIR) compared to insulin aspart.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A cross-over, open-label, randomized study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycaemia difference in time in range (TIR) 70-180mg/dl</measure>
    <time_frame>at week 4 of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycaemia difference in time in range (TIR) 70-180mg/dl</measure>
    <time_frame>at week 8 of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycaemia difference in time below range (TBR)</measure>
    <time_frame>at weeks 4 and 8 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemia difference in time above range (TAR)</measure>
    <time_frame>at weeks 4 and 8 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemia difference in the coefficient of variation (CV)</measure>
    <time_frame>at weeks 4 and 8 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the average glycemia levels + standard deviation</measure>
    <time_frame>at weeks 4 and 8 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Total Daily Dose (TDD) of insulin</measure>
    <time_frame>at weeks 4 and 8 of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the basal rate of insulin</measure>
    <time_frame>at weeks 4 and 8 of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Diabetes type1</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Insulin Aspart</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will use the continuous subcutaneous insulin infusion of insulin aspart (Novo Rapid, Novo Nordisk) and RT-CGM for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Fiasp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will use the continuous subcutaneous insulin infusion of insulin faster aspart (Fiasp, Novo Nordisk) and RT-CGM for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin faster aspart (Fiasp, Novo Nordisk)</intervention_name>
    <description>Duration of the study: 10 weeks.&#xD;
It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.&#xD;
W0: The study will start with a 2-week run-in period in order to normalize glycemia.&#xD;
W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.&#xD;
W2: after 2 weeks, diabetology telephone consultation (washout period).&#xD;
W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.&#xD;
W4: after 2 weeks, diabetology telephone consultation (washout period).&#xD;
W5: after 2 weeks, diabetology telephone consultation.&#xD;
W6: the results obtained throughout the study will be discussed with the patient and the parent.</description>
    <arm_group_label>Insulin Aspart</arm_group_label>
    <arm_group_label>Insulin Fiasp</arm_group_label>
    <other_name>Insulin aspart (Novo Rapid, Novo Nordisk)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥1 year of a history of type 1 diabetes;&#xD;
&#xD;
          -  treatment with intensive insulin therapy with the use of an insulin pump (continuous&#xD;
             subcutaneous insulin infusion, CSII) ≥3 months;&#xD;
&#xD;
          -  using continuous glucose monitoring system for at least 1 month;&#xD;
&#xD;
          -  HbA1c&lt;8%;&#xD;
&#xD;
          -  consent to participate in the study obtained from the parent and the patient (&gt;16&#xD;
             years of age).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diabetes treated with multiple insulin injections with insulin pens (Multiple Daily&#xD;
             Injections, MDI);&#xD;
&#xD;
          -  concomitant medical problems which might significantly affect glucose levels;&#xD;
&#xD;
          -  the withdrawal of the consent to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnieszka Szypowska, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatric Diabetology and Pediatrics, Pediatric Teaching Clinical Hospital of the Medical University of Warsaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilia Kowalczyk, MD</last_name>
    <phone>+48 223179538</phone>
    <email>emilia.kowalczyk@uckwum.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnieszka Szypowska, Prof.</last_name>
    <phone>+48 223179539</phone>
    <email>agnieszka.szypowska@uckwum.pl</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CGM</keyword>
  <keyword>continuous glucose monitoring system</keyword>
  <keyword>TIR</keyword>
  <keyword>Time In Range</keyword>
  <keyword>insulin aspart</keyword>
  <keyword>insulin faster aspart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

